HBIO — Harvard Bioscience, Inc.

Summary of Harvard Bioscience (HBIO) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $23.7 million, slightly above guidance ($22.5 million to $24.5 million) but down from $24.6 million in Q4 2024.
• Gross Margin: 59.7%, at the high end of guidance and up 260 basis points year-over-year.
• Adjusted EBITDA: $3.8 million, reflecting a 27% increase year-over-year.
• Operating Income: $1.7 million, improved from flat the previous year; adjusted operating income rose to $3.3 million from $2.5 million.
• Full Year Revenue: $86.6 million, down from $94.1 million in 2024, primarily due to tariffs and delayed NIH funding.
• Full Year Adjusted EBITDA: Increased 12.5% to $8.1 million.
• GAAP EPS: Negative $0.06 for Q4; full year GAAP loss per share was $1.28, worsened from negative $0.28 in 2024.

2. Strategic Updates and Business Highlights:

• Refinancing Completed: Extended debt maturity to 2021, reducing annual debt service by $3 million.
• Manufacturing Consolidation: Phased closure of the Holliston facility, expected to generate $3 million in savings by 2027.
• Leadership Changes: Appointment of Mark Frost as permanent CFO and addition of four new board members.
• Focus on Translational Science: Transitioning from traditional life science tools to enabling translational science, targeting a $10 billion market.
• Product Innovation: Emphasis on high-margin new product innovations (NPI) such as SoHo telemetry and Mesh MEA.

3. Forward Guidance and Outlook:

• Q1 2026 Revenue Guidance: Expected between $20 million and $22 million.
• Full Year 2026 Guidance: Revenue growth of 2% to 4%, gross margin of 58% to 60%, and adjusted EBITDA growth of 6% to 10%.
• Revenue Ramp-Up: Anticipated stronger NPI revenue to support growth throughout the year.

4. Bad News, Challenges, or Points of Concern:

• Full Year Revenue Decline: Down 8% year-over-year, attributed to tariffs and NIH funding delays.
• GAAP Losses: Significant GAAP losses due to a goodwill impairment charge.
• Dependence on NIH Funding: Approximately 20% of U.S. revenue is tied to NIH funding, which has been delayed.
• Geographic Revenue Challenges: Declines in revenue from the Americas and Europe, particularly in academic sales, though Asia Pacific showed improvement.

5. Notable Q&A Insights:

• NIH Funding Impact: Management expects a positive impact from NIH funding approvals towards the end of Q1 and into Q2.
• Product Growth Expectations: Key products like BTX and Mesh MEA are expected to grow in double digits in 2026.
• Backlog Status: The company ended the year with the highest backlog in over two years, indicating potential for future revenue.
• Pharmaceutical Market Demand: Demand in the pharma and biotech sectors is improving, contributing positively to the company’s guidance.

Overall, Harvard Bioscience is navigating a transitional phase with a focus on improving operational efficiency and targeting growth in the translational science market, despite facing challenges related to revenue declines and external funding dependencies.